Share on LinkedInShare on LinkedIn

ARTICLE · 14 JULY 2022

FDA To Develop Framework For Continued Expanded Access To Infant Formula

As we previously have reported, in May FDA announced an enforcement discretion policy which would allow certain non-compliant infant formula to be marketed in the U.S.

United StatesFood, Drugs, Healthcare, Life Sciences
  • As we previously have reported, in May FDA announced an enforcement discretion policy which would allow certain non-compliant infant formula to be marketed in the U.S. The policy, which will remain in effect until November 14, 2022, was intended to address the infant formula shortage that resulted from the temporary shutdown of Abbot's facility in Sturgis, Michigan due to positive test results in the facility for Cronobacter sakazakki and an outbreak of food-borne illness among infants who had been exposed to infant formula produced at the facility.
  • Last week FDA announced steps to facilitate the continued use of infant formula marketed under the enforcement discretion policy past its November 14, 2022 expiration date. Specifically, FDA announced that it would:
    • Provide a single technical assistance contact at FDA for companies aiming to enter the U.S. infant formula market.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from